drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01182 | DB11057 | 371 | 720 | [
"DDInter1534",
"DDInter1223"
] | Propafenone | Mineral oil | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
371,
24,
720
]
],
[
[
371,
24,
927
],
[
927,
63,
720
]
],
[
[
371,
24,
1151
],
[
1151,
24,
720
]
],
[
[
371,
25,
1069
],
[
1069,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Su... |
DB00819 | DB00945 | 471 | 1,479 | [
"DDInter15",
"DDInter20"
] | Acetazolamide | Acetylsalicylic acid | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Major | 2 | [
[
[
471,
25,
1479
]
],
[
[
471,
6,
10612
],
[
10612,
45,
1479
]
],
[
[
471,
21,
29250
],
[
29250,
60,
1479
]
],
[
[
471,
24,
714
],
[
714,... | [
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound... | Acetazolamide (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Acetylsalicylic acid (Compound)
Acetazolamide (Compound) causes Polyuria (Side Effect) and Polyuria (Side Effect) is caused by Acetylsalicylic acid (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when t... |
DB00015 | DB09030 | 582 | 840 | [
"DDInter1585",
"DDInter1945"
] | Reteplase | Vorapaxar | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
582,
25,
840
]
],
[
[
582,
23,
944
],
[
944,
62,
840
]
],
[
[
582,
24,
765
],
[
765,
24,
840
]
],
[
[
582,
24,
1496
],
[
1496,
6... | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a mo... |
DB00242 | DB11793 | 1,064 | 738 | [
"DDInter392",
"DDInter1297"
] | Cladribine | Niraparib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Major | 2 | [
[
[
1064,
25,
738
]
],
[
[
1064,
24,
466
],
[
466,
63,
738
]
],
[
[
1064,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1064,
63,
1253
],
[
1253,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutam... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Cladribine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause... |
DB00330 | DB06674 | 238 | 908 | [
"DDInter689",
"DDInter837"
] | Ethambutol | Golimumab | Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of _Mycob... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
238,
24,
908
]
],
[
[
238,
63,
268
],
[
268,
24,
908
]
],
[
[
238,
24,
458
],
[
458,
24,
908
]
],
[
[
238,
24,
1434
],
[
1434,
6... | [
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Ethambutol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2b"
]... | Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2b and Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Ethambutol may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00514 | DB01255 | 506 | 633 | [
"DDInter527",
"DDInter1078"
] | Dextromethorphan | Lisdexamfetamine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
506,
24,
633
]
],
[
[
506,
25,
551
],
[
551,
1,
633
]
],
[
[
506,
63,
80
],
[
80,
40,
633
]
],
[
[
506,
24,
1529
],
[
1529,
1,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
],
[... | Dextromethorphan may lead to a major life threatening interaction when taken with Phenelzine and Phenelzine (Compound) resembles Lisdexamfetamine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Lisdexamfetamine ... |
DB00467 | DB00992 | 1,467 | 842 | [
"DDInter644",
"DDInter1182"
] | Enoxacin | Methyl aminolevulinate (topical) | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
1467,
24,
842
]
],
[
[
1467,
40,
246
],
[
246,
63,
842
]
],
[
[
1467,
24,
1274
],
[
1274,
24,
842
]
],
[
[
1467,
40,
1299
],
[
1299,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cau... | Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Enoxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Enoxacin may cause a moderate inte... |
DB09068 | DB09075 | 1,427 | 498 | [
"DDInter1948",
"DDInter621"
] | Vortioxetine | Edoxaban | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
1427,
24,
498
]
],
[
[
1427,
64,
222
],
[
222,
24,
498
]
],
[
[
1427,
24,
1017
],
[
1017,
63,
498
]
],
[
[
1427,
63,
129
],
[
129,
... | [
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Vortioxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Vortioxetine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may ca... |
DB00339 | DB00445 | 1,182 | 322 | [
"DDInter1547",
"DDInter655"
] | Pyrazinamide | Epirubicin | A pyrazine that is used therapeutically as an antitubercular agent. | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Moderate | 1 | [
[
[
1182,
24,
322
]
],
[
[
1182,
21,
28828
],
[
28828,
60,
322
]
],
[
[
1182,
24,
482
],
[
482,
24,
322
]
],
[
[
1182,
24,
384
],
[
384,
... | [
[
[
"Pyrazinamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
]
],
[
[
"Pyrazinamide",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reactio... | Pyrazinamide (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Epirubicin (Compound)
Pyrazinamide may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerb... |
DB00261 | DB01263 | 702 | 859 | [
"DDInter93",
"DDInter1494"
] | Anagrelide | Posaconazole | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
702,
25,
859
]
],
[
[
702,
21,
28762
],
[
28762,
60,
859
]
],
[
[
702,
23,
112
],
[
112,
23,
859
]
],
[
[
702,
24,
286
],
[
286,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Anagrelide",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Comp... | Anagrelide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Posac... |
DB00472 | DB08875 | 758 | 1,618 | [
"DDInter758",
"DDInter262"
] | Fluoxetine | Cabozantinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
758,
25,
1618
]
],
[
[
758,
23,
112
],
[
112,
23,
1618
]
],
[
[
758,
24,
1662
],
[
1662,
63,
1618
]
],
[
[
758,
24,
480
],
[
480,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid... |
DB00549 | DB12130 | 522 | 1,017 | [
"DDInter1955",
"DDInter1094"
] | Zafirlukast | Lorlatinib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
522,
24,
1017
]
],
[
[
522,
23,
271
],
[
271,
23,
1017
]
],
[
[
522,
24,
786
],
[
786,
24,
1017
]
],
[
[
522,
63,
201
],
[
201,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
... | Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivi... |
DB00169 | DB09407 | 386 | 853 | [
"DDInter367",
"DDInter1114"
] | Cholecalciferol | Magnesium chloride | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
386,
24,
853
]
],
[
[
386,
24,
544
],
[
544,
24,
853
]
],
[
[
386,
24,
460
],
[
460,
63,
853
]
],
[
[
386,
75,
1331
],
[
1331,
2... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Cholecalciferol may cause a moderate interaction that could exacerbate diseases when ... |
DB03619 | DB05773 | 557 | 1,047 | [
"DDInter501",
"DDInter1848"
] | Deoxycholic acid | Trastuzumab emtansine | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
557,
24,
1047
]
],
[
[
557,
63,
714
],
[
714,
24,
1047
]
],
[
[
557,
63,
1018
],
[
1018,
25,
1047
]
],
[
[
557,
24,
1409
],
[
1409,
... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ilop... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Ti... |
DB00792 | DB01215 | 832 | 1,418 | [
"DDInter1878",
"DDInter677"
] | Tripelennamine | Estazolam | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam. | Moderate | 1 | [
[
[
832,
24,
1418
]
],
[
[
832,
63,
523
],
[
523,
1,
1418
]
],
[
[
832,
63,
1216
],
[
1216,
40,
1418
]
],
[
[
832,
24,
481
],
[
481,
... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprazolam"
],
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Estazolam (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Estazolam (Comp... |
DB00377 | DB00978 | 1,494 | 739 | [
"DDInter1382",
"DDInter1084"
] | Palonosetron | Lomefloxacin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Moderate | 1 | [
[
[
1494,
24,
739
]
],
[
[
1494,
25,
945
],
[
945,
40,
739
]
],
[
[
1494,
24,
872
],
[
872,
40,
739
]
],
[
[
1494,
64,
1176
],
[
1176,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
],
[
"Sp... | Palonosetron may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Lomefloxacin (Compound)... |
DB00802 | DB00835 | 1,322 | 100 | [
"DDInter43",
"DDInter245"
] | Alfentanil | Brompheniramine | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1322,
24,
100
]
],
[
[
1322,
63,
832
],
[
832,
24,
100
]
],
[
[
1322,
24,
649
],
[
649,
63,
100
]
],
[
[
1322,
6,
8374
],
[
8374,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Clofedan... |
DB00539 | DB01182 | 11 | 371 | [
"DDInter1837",
"DDInter1534"
] | Toremifene | Propafenone | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Major | 2 | [
[
[
11,
25,
371
]
],
[
[
11,
64,
847
],
[
847,
1,
371
]
],
[
[
11,
1,
1661
],
[
1661,
40,
371
]
],
[
[
11,
1,
11234
],
[
11234,
1,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Propafenone"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u... | Toremifene may lead to a major life threatening interaction when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Toremifene (Compound) resembles Phenoxybenzamine (Compound) and Phenoxybenzamine (Compound) resembles Propafenone (Compound)
Toremifene (Compound) resembles Benzyl Benzoate... |
DB00005 | DB10989 | 1,057 | 496 | [
"DDInter687",
"DDInter858"
] | Etanercept | Hepatitis A Vaccine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1057,
24,
496
]
],
[
[
1057,
25,
1093
],
[
1093,
63,
496
]
],
[
[
1057,
25,
4
],
[
4,
24,
496
]
],
[
[
1057,
64,
669
],
[
669,
2... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"I... | Etanercept may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Etanercept may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine ... |
DB00026 | DB12332 | 1,184 | 1,619 | [
"DDInter94",
"DDInter1626"
] | Anakinra | Rucaparib | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1184,
24,
1619
]
],
[
[
1184,
24,
259
],
[
259,
24,
1619
]
],
[
[
1184,
24,
151
],
[
151,
63,
1619
]
],
[
[
1184,
25,
1259
],
[
1259,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/Califo... |
DB00022 | DB00446 | 268 | 597 | [
"DDInter1408",
"DDInter351"
] | Peginterferon alfa-2b | Chloramphenicol | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
268,
24,
597
]
],
[
[
268,
25,
1101
],
[
1101,
23,
597
]
],
[
[
268,
24,
1627
],
[
1627,
62,
597
]
],
[
[
268,
23,
450
],
[
450,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
... | Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol... |
DB01073 | DB08868 | 1,488 | 1,011 | [
"DDInter745",
"DDInter737"
] | Fludarabine | Fingolimod | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1488,
25,
1011
]
],
[
[
1488,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
1488,
63,
112
],
[
112,
23,
1011
]
],
[
[
1488,
24,
748
],
[
748... | [
[
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Fludarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (S... | Fludarabine (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit cl... |
DB00222 | DB06203 | 245 | 1,002 | [
"DDInter825",
"DDInter51"
] | Glimepiride | Alogliptin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
245,
24,
1002
]
],
[
[
245,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
245,
21,
29340
],
[
29340,
60,
1002
]
],
[
[
245,
23,
1103
],
[
1103... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Glimepiride (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Alogliptin (Compound)
Glimepirid... |
DB00377 | DB01165 | 1,494 | 1,539 | [
"DDInter1382",
"DDInter1325"
] | Palonosetron | Ofloxacin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1494,
24,
1539
]
],
[
[
1494,
64,
1176
],
[
1176,
1,
1539
]
],
[
[
1494,
25,
945
],
[
945,
40,
1539
]
],
[
[
1494,
24,
956
],
[
956,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxif... | Palonosetron may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Palonosetron may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Palonosetron may cau... |
DB01033 | DB12674 | 328 | 975 | [
"DDInter1156",
"DDInter1105"
] | Mercaptopurine | Lurbinectedin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
328,
24,
975
]
],
[
[
328,
24,
1488
],
[
1488,
24,
975
]
],
[
[
328,
63,
372
],
[
372,
24,
975
]
],
[
[
328,
74,
482
],
[
482,
2... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Clofarab... |
DB00443 | DB01336 | 251 | 545 | [
"DDInter195",
"DDInter1198"
] | Betamethasone | Metocurine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. | Moderate | 1 | [
[
[
251,
24,
545
]
],
[
[
251,
24,
1217
],
[
1217,
40,
545
]
],
[
[
251,
63,
1031
],
[
1031,
24,
545
]
],
[
[
251,
1,
1486
],
[
1486,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Tubocurarine and Tubocurarine (Compound) resembles Metocurine (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interact... |
DB00222 | DB00477 | 245 | 216 | [
"DDInter825",
"DDInter363"
] | Glimepiride | Chlorpromazine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
245,
24,
216
]
],
[
[
245,
24,
1178
],
[
1178,
1,
216
]
],
[
[
245,
24,
684
],
[
684,
40,
216
]
],
[
[
245,
21,
28751
],
[
28751,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Ch... |
DB00687 | DB01116 | 870 | 601 | [
"DDInter747",
"DDInter1872"
] | Fludrocortisone | Trimethaphan | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery. | Moderate | 1 | [
[
[
870,
24,
601
]
],
[
[
870,
24,
998
],
[
998,
1,
601
]
],
[
[
870,
25,
593
],
[
593,
63,
601
]
],
[
[
870,
1,
891
],
[
891,
24,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethaphan"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutazone"... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and Phenylbutazone (Compound) resembles Trimethaphan (Compound)
Fludrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that co... |
DB08899 | DB15233 | 129 | 1,650 | [
"DDInter649",
"DDInter142"
] | Enzalutamide | Avapritinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
129,
25,
1650
]
],
[
[
129,
64,
1478
],
[
1478,
24,
1650
]
],
[
[
129,
63,
1101
],
[
1101,
24,
1650
]
],
[
[
129,
25,
159
],
[
159,
... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u... | Enzalutamide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cau... |
DB00563 | DB08913 | 663 | 1,186 | [
"DDInter1174",
"DDInter1561"
] | Methotrexate | Radium Ra 223 dichloride | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
663,
24,
1186
]
],
[
[
663,
21,
28872
],
[
28872,
60,
1186
]
],
[
[
663,
24,
37
],
[
37,
24,
1186
]
],
[
[
663,
63,
134
],
[
134,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Extravasation"
],
[
"Extravasation",
... | Methotrexate (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases... |
DB01222 | DB15982 | 617 | 1,339 | [
"DDInter246",
"DDInter193"
] | Budesonide | Berotralstat | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Berotralstat is a selective inhibitor of plasma kallikrein used in the prophylaxis of attacks of hereditary angioedema (HAE). It works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE. Berotralstat ... | Moderate | 1 | [
[
[
617,
24,
1339
]
],
[
[
617,
24,
283
],
[
283,
23,
1339
]
],
[
[
617,
24,
1213
],
[
1213,
24,
1339
]
],
[
[
617,
40,
1486
],
[
1486,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
... | Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Berotralstat
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatin... |
DB04868 | DB06817 | 478 | 809 | [
"DDInter1293",
"DDInter1563"
] | Nilotinib | Raltegravir | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. | Minor | 0 | [
[
[
478,
23,
809
]
],
[
[
478,
6,
15705
],
[
15705,
45,
809
]
],
[
[
478,
7,
3727
],
[
3727,
46,
809
]
],
[
[
478,
21,
29122
],
[
29122,
... | [
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Raltegravir"
]
],
[
[
"Nilotinib",
"{u} (Compound) binds {v} (Gene)",
"UGT1A1"
],
[
"UGT1A1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nilotinib (Compound) binds UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Raltegravir (Compound)
Nilotinib (Compound) upregulates MAL (Gene) and MAL (Gene) is upregulated by Raltegravir (Compound)
Nilotinib (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Raltegravir... |
DB00002 | DB00460 | 1,284 | 612 | [
"DDInter344",
"DDInter1929"
] | Cetuximab | Verteporfin | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it... | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Moderate | 1 | [
[
[
1284,
24,
612
]
],
[
[
1284,
24,
842
],
[
842,
63,
612
]
],
[
[
1284,
25,
213
],
[
213,
64,
612
]
],
[
[
1284,
24,
842
],
[
842,
... | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
... | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin
Cetuximab may lead to a major life threatening interaction when taken with Aminolevulini... |
DB00443 | DB00661 | 251 | 122 | [
"DDInter195",
"DDInter1928"
] | Betamethasone | Verapamil | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Moderate | 1 | [
[
[
251,
24,
122
]
],
[
[
251,
6,
8374
],
[
8374,
45,
122
]
],
[
[
251,
7,
5918
],
[
5918,
45,
122
]
],
[
[
251,
18,
3106
],
[
3106,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verapamil"
]
],
[
[
"Betamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Verapamil (Compound)
Betamethasone (Compound) upregulates SLC22A5 (Gene) and SLC22A5 (Gene) is bound by Verapamil (Compound)
Betamethasone (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Verapamil (Compound)
Betameth... |
DB00674 | DB01362 | 1,516 | 497 | [
"DDInter802",
"DDInter960"
] | Galantamine | Iohexol | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1516,
25,
497
]
],
[
[
1516,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1516,
63,
999
],
[
999,
25,
497
]
],
[
[
1516,
24,
1264
],
[
1264,... | [
[
[
"Galantamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused... | Galantamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken wi... |
DB00418 | DB06282 | 536 | 516 | [
"DDInter1650",
"DDInter1053"
] | Secobarbital | Levocetirizine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
536,
24,
516
]
],
[
[
536,
63,
1031
],
[
1031,
23,
516
]
],
[
[
536,
63,
701
],
[
701,
24,
516
]
],
[
[
536,
24,
1614
],
[
1614,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clemastine ... |
DB00270 | DB09112 | 1,428 | 1,455 | [
"DDInter993",
"DDInter1306"
] | Isradipine | Nitrous acid | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applica... | Moderate | 1 | [
[
[
1428,
24,
1455
]
],
[
[
1428,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1428,
1,
336
],
[
336,
24,
1455
]
],
[
[
1428,
40,
854
],
[
854,
... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Isradipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a moderate interaction th... |
DB00635 | DB14443 | 1,573 | 987 | [
"DDInter1515",
"DDInter1931"
] | Prednisone | Vibrio cholerae CVD 103-HgR strain live antigen | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1573,
24,
987
]
],
[
[
1573,
1,
1220
],
[
1220,
24,
987
]
],
[
[
1573,
24,
351
],
[
351,
24,
987
]
],
[
[
1573,
63,
305
],
[
305,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dex... | Prednisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib ... |
DB00802 | DB00986 | 1,322 | 1,192 | [
"DDInter43",
"DDInter834"
] | Alfentanil | Glycopyrronium | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
1322,
24,
1192
]
],
[
[
1322,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
1322,
63,
262
],
[
262,
24,
1192
]
],
[
[
1322,
21,
29231
],
[
292... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and C... |
DB00278 | DB06603 | 291 | 39 | [
"DDInter117",
"DDInter1387"
] | Argatroban | Panobinostat | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
291,
25,
39
]
],
[
[
291,
24,
578
],
[
578,
63,
39
]
],
[
[
291,
63,
599
],
[
599,
24,
39
]
],
[
[
291,
24,
383
],
[
383,
24,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrel... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Ale... |
DB06655 | DB14509 | 5 | 1,399 | [
"DDInter1077",
"DDInter1081"
] | Liraglutide | Lithium carbonate | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
5,
24,
1399
]
],
[
[
5,
63,
874
],
[
874,
23,
1399
]
],
[
[
5,
63,
820
],
[
820,
24,
1399
]
],
[
[
5,
24,
1296
],
[
1296,
24,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine ... |
DB08895 | DB12159 | 976 | 12 | [
"DDInter1825",
"DDInter609"
] | Tofacitinib | Dupilumab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that indu... | Major | 2 | [
[
[
976,
25,
12
]
],
[
[
976,
62,
1461
],
[
1461,
23,
12
]
],
[
[
976,
23,
1114
],
[
1114,
23,
12
]
],
[
[
976,
64,
599
],
[
599,
24... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dupilumab"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Dupilumab
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfat... |
DB00762 | DB14575 | 613 | 733 | [
"DDInter973",
"DDInter674"
] | Irinotecan | Eslicarbazepine | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
613,
24,
733
]
],
[
[
613,
63,
1101
],
[
1101,
23,
733
]
],
[
[
613,
24,
1491
],
[
1491,
24,
733
]
],
[
[
613,
25,
129
],
[
129,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mi... |
DB00431 | DB00454 | 1,503 | 1,349 | [
"DDInter1072",
"DDInter1150"
] | Lindane | Meperidine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Moderate | 1 | [
[
[
1503,
24,
1349
]
],
[
[
1503,
24,
901
],
[
901,
1,
1349
]
],
[
[
1503,
21,
28762
],
[
28762,
60,
1349
]
],
[
[
1503,
63,
73
],
[
73,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound)
Lindane (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Meperidine (Compound)
Lindane may cause a moderate interaction that coul... |
DB01181 | DB04844 | 1,532 | 843 | [
"DDInter906",
"DDInter1778"
] | Ifosfamide | Tetrabenazine | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
1532,
24,
843
]
],
[
[
1532,
21,
29093
],
[
29093,
60,
843
]
],
[
[
1532,
63,
1555
],
[
1555,
24,
843
]
],
[
[
1532,
24,
129
],
[
129,... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Ifosfamide",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is cause... | Ifosfamide (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Tetrabenazine (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tetrab... |
DB00683 | DB11718 | 1,382 | 927 | [
"DDInter1212",
"DDInter640"
] | Midazolam | Encorafenib | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1382,
24,
927
]
],
[
[
1382,
63,
1324
],
[
1324,
24,
927
]
],
[
[
1382,
24,
770
],
[
770,
24,
927
]
],
[
[
1382,
24,
484
],
[
484,
... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
... | Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Th... |
DB00278 | DB05578 | 291 | 330 | [
"DDInter117",
"DDInter1566"
] | Argatroban | Ramucirumab | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
291,
25,
330
]
],
[
[
291,
24,
41
],
[
41,
63,
330
]
],
[
[
291,
24,
901
],
[
901,
24,
330
]
],
[
[
291,
63,
1230
],
[
1230,
24,... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levo... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Milnacipra... |
DB00067 | DB00816 | 317 | 1,674 | [
"DDInter1921",
"DDInter1346"
] | Vasopressin | Orciprenaline | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
317,
24,
1674
]
],
[
[
317,
24,
874
],
[
874,
24,
1674
]
],
[
[
317,
24,
870
],
[
870,
23,
1674
]
],
[
[
317,
24,
484
],
[
484,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortison... |
DB06688 | DB11834 | 1,430 | 1,303 | [
"DDInter1677",
"DDInter849"
] | Sipuleucel-T | Guselkumab | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
1430,
24,
1303
]
],
[
[
1430,
24,
713
],
[
713,
24,
1303
]
],
[
[
1430,
63,
58
],
[
58,
24,
1303
]
],
[
[
1430,
24,
287
],
[
287,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ale... |
DB00294 | DB09043 | 1,336 | 135 | [
"DDInter701",
"DDInter36"
] | Etonogestrel | Albiglutide | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1336,
24,
135
]
],
[
[
1336,
63,
1647
],
[
1647,
23,
135
]
],
[
[
1336,
63,
176
],
[
176,
24,
135
]
],
[
[
1336,
24,
629
],
[
629,
... | [
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Etonogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
[... | Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and I... |
DB00342 | DB00726 | 1,181 | 1,164 | [
"DDInter1770",
"DDInter1876"
] | Terfenadine | Trimipramine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
1181,
24,
1164
]
],
[
[
1181,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
1181,
64,
576
],
[
576,
40,
1164
]
],
[
[
1181,
63,
21
],
[
21,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Terfenadine may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Trimipramine (Compound)
Terfena... |
DB00814 | DB08820 | 1,171 | 1,478 | [
"DDInter1143",
"DDInter997"
] | Meloxicam | Ivacaftor | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Moderate | 1 | [
[
[
1171,
24,
1478
]
],
[
[
1171,
6,
8374
],
[
8374,
45,
1478
]
],
[
[
1171,
21,
30495
],
[
30495,
60,
1478
]
],
[
[
1171,
24,
1411
],
[
1... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
]
],
[
[
"Meloxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Meloxicam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Meloxicam (Compound) causes Pleuritic pain (Side Effect) and Pleuritic pain (Side Effect) is caused by Ivacaftor (Compound)
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide an... |
DB01246 | DB11986 | 820 | 484 | [
"DDInter45",
"DDInter648"
] | Alimemazine | Entrectinib | A phenothiazine derivative that is used as an antipruritic. | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
820,
24,
484
]
],
[
[
820,
62,
1247
],
[
1247,
23,
484
]
],
[
[
820,
63,
222
],
[
222,
23,
484
]
],
[
[
820,
63,
1539
],
[
1539,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramin... |
DB00397 | DB01088 | 1,466 | 714 | [
"DDInter1458",
"DDInter908"
] | Phenylpropanolamine | Iloprost | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1466,
24,
714
]
],
[
[
1466,
25,
318
],
[
318,
63,
714
]
],
[
[
1466,
35,
1445
],
[
1445,
24,
714
]
],
[
[
1466,
25,
758
],
[
758,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Phenylpropanolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[... | Phenylpropanolamine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Phenylpropanolamine (Compound) resembles Pseudoephedrine (Compound) and Phenylpropanolamine may cause a moderate int... |
DB01320 | DB11827 | 651 | 433 | [
"DDInter783",
"DDInter669"
] | Fosphenytoin | Ertugliflozin | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
651,
24,
433
]
],
[
[
651,
63,
959
],
[
959,
24,
433
]
],
[
[
651,
40,
362
],
[
362,
24,
433
]
],
[
[
651,
25,
1033
],
[
1033,
6... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Fosphenytoin (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that co... |
DB01088 | DB01242 | 714 | 1,237 | [
"DDInter908",
"DDInter410"
] | Iloprost | Clomipramine | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
714,
24,
1237
]
],
[
[
714,
63,
1578
],
[
1578,
24,
1237
]
],
[
[
714,
24,
397
],
[
397,
63,
1237
]
],
[
[
714,
25,
498
],
[
498,
... | [
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lepirudin"
],
[
... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin and Plicamycin... |
DB00373 | DB11827 | 461 | 433 | [
"DDInter1809",
"DDInter669"
] | Timolol | Ertugliflozin | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
461,
24,
433
]
],
[
[
461,
24,
959
],
[
959,
24,
433
]
],
[
[
461,
63,
999
],
[
999,
24,
433
]
],
[
[
461,
62,
1152
],
[
1152,
2... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiet... |
DB00912 | DB06203 | 473 | 1,002 | [
"DDInter1581",
"DDInter51"
] | Repaglinide | Alogliptin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
473,
24,
1002
]
],
[
[
473,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
473,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
473,
21,
28873
],
[
28873,... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Repaglinide (Compound) causes Pancreatitis (Side Effect) and P... |
DB01143 | DB01359 | 923 | 729 | [
"DDInter65",
"DDInter1417"
] | Amifostine | Penbutolol | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
923,
24,
729
]
],
[
[
923,
63,
461
],
[
461,
1,
729
]
],
[
[
923,
24,
699
],
[
699,
40,
729
]
],
[
[
923,
21,
28695
],
[
28695,
... | [
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Amifostine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Amifostine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Amifostine (... |
DB00526 | DB06772 | 1,555 | 310 | [
"DDInter1355",
"DDInter259"
] | Oxaliplatin | Cabazitaxel | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
1555,
24,
310
]
],
[
[
1555,
24,
973
],
[
973,
24,
310
]
],
[
[
1555,
6,
17404
],
[
17404,
45,
310
]
],
[
[
1555,
25,
868
],
[
868,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Oxaliplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Cabazitaxel (Compound)
Oxaliplatin may ... |
DB00398 | DB08864 | 79 | 786 | [
"DDInter1702",
"DDInter1595"
] | Sorafenib | Rilpivirine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
79,
24,
786
]
],
[
[
79,
24,
655
],
[
655,
1,
786
]
],
[
[
79,
6,
8374
],
[
8374,
45,
786
]
],
[
[
79,
21,
28734
],
[
28734,
60,... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etravirine"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine and Etravirine (Compound) resembles Rilpivirine (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Sorafenib (Compound) causes Immune system disorder (Side Effect) a... |
DB00761 | DB00986 | 1,621 | 1,192 | [
"DDInter1497",
"DDInter834"
] | Potassium chloride | Glycopyrronium | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Major | 2 | [
[
[
1621,
25,
1192
]
],
[
[
1621,
25,
1511
],
[
1511,
63,
1192
]
],
[
[
1621,
25,
262
],
[
262,
24,
1192
]
],
[
[
1621,
21,
29188
],
[
291... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepenzolate"
],
[
"Mepe... | Potassium chloride may lead to a major life threatening interaction when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Potassium chloride may lead to a major life threatening interaction when taken with Clidinium and Clidinium may c... |
DB00862 | DB11057 | 1,005 | 720 | [
"DDInter1918",
"DDInter1223"
] | Vardenafil | Mineral oil | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1005,
24,
720
]
],
[
[
1005,
24,
927
],
[
927,
63,
720
]
],
[
[
1005,
24,
1151
],
[
1151,
24,
720
]
],
[
[
1005,
25,
1069
],
[
1069,
... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Vardenafil may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Suni... |
DB00448 | DB01254 | 1,215 | 1,213 | [
"DDInter1022",
"DDInter484"
] | Lansoprazole | Dasatinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1215,
25,
1213
]
],
[
[
1215,
6,
17404
],
[
17404,
45,
1213
]
],
[
[
1215,
18,
7458
],
[
7458,
46,
1213
]
],
[
[
1215,
18,
4112
],
[
4... | [
[
[
"Lansoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Dasati... | Lansoprazole (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Dasatinib (Compound)
Lansoprazole (Compound) downregulates TGFB3 (Gene) and TGFB3 (Gene) is upregulated by Dasatinib (Compound)
Lansoprazole (Compound) downregulates AURKB (Gene) and AURKB (Gene) is downregulated by Dasatinib (Compound)
Lansoprazol... |
DB01218 | DB01591 | 1,493 | 667 | [
"DDInter852",
"DDInter1696"
] | Halofantrine | Solifenacin | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Major | 2 | [
[
[
1493,
25,
667
]
],
[
[
1493,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1493,
21,
28703
],
[
28703,
60,
667
]
],
[
[
1493,
62,
112
],
[
112,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
],
[
[
"Halofantrine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"So... | Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Halofantrine (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Solifenacin (Compound)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Metronidazole a... |
DB00459 | DB09061 | 640 | 1,627 | [
"DDInter21",
"DDInter284"
] | Acitretin | Cannabidiol | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
640,
24,
1627
]
],
[
[
640,
24,
384
],
[
384,
23,
1627
]
],
[
[
640,
24,
1613
],
[
1613,
63,
1627
]
],
[
[
640,
24,
267
],
[
267,
... | [
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a an... |
DB00009 | DB00302 | 1,271 | 335 | [
"DDInter56",
"DDInter1844"
] | Alteplase | Tranexamic acid | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Moderate | 1 | [
[
[
1271,
24,
335
]
],
[
[
1271,
24,
578
],
[
578,
62,
335
]
],
[
[
1271,
23,
1631
],
[
1631,
62,
20
],
[
20,
24,
335
]
],
[
[
1271,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tranexamic acid"
]
],
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[... | Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Tranexamic acid
Alteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric ... |
DB00247 | DB12130 | 1,131 | 1,017 | [
"DDInter1194",
"DDInter1094"
] | Methysergide | Lorlatinib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1131,
24,
1017
]
],
[
[
1131,
24,
1101
],
[
1101,
23,
1017
]
],
[
[
1131,
24,
1446
],
[
1446,
24,
1017
]
],
[
[
1131,
40,
588
],
[
588... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanr... |
DB00374 | DB06754 | 1,061 | 707 | [
"DDInter1852",
"DDInter471"
] | Treprostinil | Danaparoid | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans . The active constituents are heparan, dermatan and , and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity t... | Major | 2 | [
[
[
1061,
25,
707
]
],
[
[
1061,
23,
944
],
[
944,
62,
707
]
],
[
[
1061,
24,
863
],
[
863,
24,
707
]
],
[
[
1061,
24,
1004
],
[
1004,
... | [
[
[
"Treprostinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
]
],
[
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile... | Treprostinil may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Danaparoid
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amiloride and Amiloride... |
DB00388 | DB08907 | 1,636 | 1,344 | [
"DDInter1453",
"DDInter280"
] | Phenylephrine | Canagliflozin | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1636,
24,
1344
]
],
[
[
1636,
24,
549
],
[
549,
1,
1344
]
],
[
[
1636,
21,
28681
],
[
28681,
60,
1344
]
],
[
[
1636,
24,
1523
],
[
152... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Phenylephrine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Canagliflozin (Compound)
Phenylephrin... |
DB01599 | DB09104 | 1,232 | 286 | [
"DDInter1523",
"DDInter1118"
] | Probucol | Magnesium hydroxide | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1232,
24,
286
]
],
[
[
1232,
63,
401
],
[
401,
23,
286
]
],
[
[
1232,
63,
688
],
[
688,
24,
286
]
],
[
[
1232,
25,
1593
],
[
1593,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Probucol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and... |
DB00604 | DB09083 | 1,425 | 880 | [
"DDInter385",
"DDInter996"
] | Cisapride | Ivabradine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1425,
25,
880
]
],
[
[
1425,
24,
480
],
[
480,
24,
880
]
],
[
[
1425,
24,
159
],
[
159,
63,
880
]
],
[
[
1425,
25,
1148
],
[
1148,
... | [
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",... | Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larot... |
DB00366 | DB09128 | 1,594 | 1,241 | [
"DDInter600",
"DDInter231"
] | Doxylamine | Brexpiprazole | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1594,
24,
1241
]
],
[
[
1594,
24,
407
],
[
407,
63,
1241
]
],
[
[
1594,
24,
543
],
[
543,
24,
1241
]
],
[
[
1594,
35,
272
],
[
272,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide ma... |
DB01191 | DB01294 | 1,039 | 266 | [
"DDInter518",
"DDInter215"
] | Dexfenfluramine | Bismuth subsalicylate | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1039,
24,
266
]
],
[
[
1039,
63,
1347
],
[
1347,
24,
266
]
],
[
[
1039,
24,
235
],
[
235,
63,
266
]
],
[
[
1039,
24,
885
],
[
885,
... | [
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopid... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01004 | DB05015 | 563 | 1,077 | [
"DDInter806",
"DDInter174"
] | Ganciclovir | Belinostat | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Moderate | 1 | [
[
[
563,
24,
1077
]
],
[
[
563,
63,
482
],
[
482,
24,
1077
]
],
[
[
563,
24,
869
],
[
869,
24,
1077
]
],
[
[
563,
24,
1250
],
[
1250,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topot... |
DB01234 | DB12267 | 1,220 | 1,476 | [
"DDInter513",
"DDInter233"
] | Dexamethasone | Brigatinib | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Major | 2 | [
[
[
1220,
25,
1476
]
],
[
[
1220,
23,
1612
],
[
1612,
23,
1476
]
],
[
[
1220,
24,
1135
],
[
1135,
23,
1476
]
],
[
[
1220,
62,
168
],
[
168... | [
[
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fostemsavir"
],
[
"Foste... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Nal... |
DB05773 | DB11793 | 1,047 | 738 | [
"DDInter1848",
"DDInter1297"
] | Trastuzumab emtansine | Niraparib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1047,
24,
738
]
],
[
[
1047,
64,
1213
],
[
1213,
24,
738
]
],
[
[
1047,
63,
663
],
[
663,
24,
738
]
],
[
[
1047,
24,
1155
],
[
1155,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
... | Trastuzumab emtansine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and ... |
DB00514 | DB04837 | 506 | 649 | [
"DDInter527",
"DDInter407"
] | Dextromethorphan | Clofedanol | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
506,
24,
649
]
],
[
[
506,
24,
1376
],
[
1376,
24,
649
]
],
[
[
506,
24,
675
],
[
675,
40,
649
]
],
[
[
506,
25,
1301
],
[
1301,
... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with... |
DB06288 | DB08868 | 607 | 1,011 | [
"DDInter77",
"DDInter737"
] | Amisulpride | Fingolimod | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
607,
25,
1011
]
],
[
[
607,
21,
28892
],
[
28892,
60,
1011
]
],
[
[
607,
62,
112
],
[
112,
23,
1011
]
],
[
[
607,
24,
144
],
[
144,
... | [
[
[
"Amisulpride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused ... | Amisulpride (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Amisulpride may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when take... |
DB01246 | DB13139 | 820 | 1,032 | [
"DDInter45",
"DDInter1063"
] | Alimemazine | Levosalbutamol | A phenothiazine derivative that is used as an antipruritic. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
820,
24,
1032
]
],
[
[
820,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
820,
24,
124
],
[
124,
24,
1032
]
],
[
[
820,
63,
1133
],
[
1133,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Ca... | Alimemazine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib ma... |
DB06237 | DB09038 | 438 | 1,450 | [
"DDInter141",
"DDInter636"
] | Avanafil | Empagliflozin | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
438,
24,
1450
]
],
[
[
438,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
438,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
438,
24,
129
],
[
129,
... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lor... |
DB00939 | DB08895 | 1,338 | 976 | [
"DDInter1135",
"DDInter1825"
] | Meclofenamic acid | Tofacitinib | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1338,
24,
976
]
],
[
[
1338,
74,
1512
],
[
1512,
24,
976
]
],
[
[
1338,
24,
1479
],
[
1479,
24,
976
]
],
[
[
1338,
63,
1274
],
[
1274,... | [
[
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Meclofenamic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseas... | Meclofenamic acid (Compound) resembles Diclofenac (Compound) and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Meclofenamic acid may cause a moderate ... |
DB09054 | DB12674 | 384 | 975 | [
"DDInter905",
"DDInter1105"
] | Idelalisib | Lurbinectedin | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
384,
25,
975
]
],
[
[
384,
63,
1488
],
[
1488,
24,
975
]
],
[
[
384,
24,
1613
],
[
1613,
24,
975
]
],
[
[
384,
25,
159
],
[
159,
... | [
[
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludar... | Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon be... |
DB00398 | DB01177 | 79 | 77 | [
"DDInter1702",
"DDInter904"
] | Sorafenib | Idarubicin | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
79,
24,
77
]
],
[
[
79,
6,
6017
],
[
6017,
45,
77
]
],
[
[
79,
18,
5440
],
[
5440,
46,
77
]
],
[
[
79,
7,
1898
],
[
1898,
46,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Sorafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Sorafenib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Sorafenib (Compound) downregulates SOX2 (Gene) and SOX2 (Gene) is upregulated by Idarubicin (Compound)
Sorafenib (Compound) upregulates GADD45A (Gene) and GADD45A (Gene) is upregulated by Idarubicin (Compound)
Sorafenib (Compou... |
DB00227 | DB00694 | 1,463 | 51 | [
"DDInter1098",
"DDInter485"
] | Lovastatin | Daunorubicin | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1463,
24,
51
]
],
[
[
1463,
6,
4973
],
[
4973,
45,
51
]
],
[
[
1463,
7,
3466
],
[
3466,
46,
51
]
],
[
[
1463,
18,
6168
],
[
6168,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Daunorubicin (Compound)
Lovastatin (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Daunorubicin (Compound)
Lovastatin (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is upregulated by Daunorubicin (Compound)
Lovastatin... |
DB01173 | DB01409 | 358 | 1,415 | [
"DDInter1349",
"DDInter1815"
] | Orphenadrine | Tiotropium | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
358,
24,
1415
]
],
[
[
358,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
358,
21,
28722
],
[
28722,
60,
1415
]
],
[
[
358,
63,
1594
],
[
1594,... | [
[
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Orphenadrine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)... | Orphenadrine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Orphenadrine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Tiotropium (Compound)
Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxyla... |
DB00372 | DB01037 | 999 | 1,161 | [
"DDInter1793",
"DDInter1653"
] | Thiethylperazine | Selegiline | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
999,
24,
1161
]
],
[
[
999,
24,
551
],
[
551,
1,
1161
]
],
[
[
999,
63,
80
],
[
80,
40,
1161
]
],
[
[
999,
24,
633
],
[
633,
40,... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Selegili... |
DB00443 | DB00816 | 251 | 1,674 | [
"DDInter195",
"DDInter1346"
] | Betamethasone | Orciprenaline | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Minor | 0 | [
[
[
251,
23,
1674
]
],
[
[
251,
5,
11649
],
[
11649,
44,
1674
]
],
[
[
251,
18,
3222
],
[
3222,
46,
1674
]
],
[
[
251,
7,
6858
],
[
6858,
... | [
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
]
],
[
[
"Betamethasone",
"{u} (Compound) treats {v} (Disease)",
"asthma"
],
[
"asthma",
"{u} (Disease) is treated by ... | Betamethasone (Compound) treats asthma (Disease) and asthma (Disease) is treated by Orciprenaline (Compound)
Betamethasone (Compound) downregulates DUSP4 (Gene) and DUSP4 (Gene) is upregulated by Orciprenaline (Compound)
Betamethasone (Compound) upregulates LPL (Gene) and LPL (Gene) is upregulated by Orciprenaline (Com... |
DB00963 | DB01222 | 1,263 | 617 | [
"DDInter241",
"DDInter246"
] | Bromfenac | Budesonide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
1263,
24,
617
]
],
[
[
1263,
63,
251
],
[
251,
1,
617
]
],
[
[
1263,
24,
1220
],
[
1220,
1,
617
]
],
[
[
1263,
7,
2216
],
[
2216,
... | [
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (... |
DB01182 | DB09291 | 371 | 741 | [
"DDInter1534",
"DDInter1615"
] | Propafenone | Rolapitant | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
371,
24,
741
]
],
[
[
371,
63,
506
],
[
506,
24,
741
]
],
[
[
371,
24,
159
],
[
159,
63,
741
]
],
[
[
371,
40,
847
],
[
847,
24,... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
... | Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Larotre... |
DB09046 | DB11853 | 1,094 | 230 | [
"DDInter1201",
"DDInter1577"
] | Metreleptin | Relugolix | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under th... | Minor | 0 | [
[
[
1094,
23,
230
]
],
[
[
1094,
24,
1476
],
[
1476,
62,
230
]
],
[
[
1094,
24,
1456
],
[
1456,
24,
230
]
],
[
[
1094,
63,
1213
],
[
1213,... | [
[
[
"Metreleptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Relugolix
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoc... |
DB01042 | DB10343 | 1,307 | 962 | [
"DDInter1144",
"DDInter160"
] | Melphalan | Bacillus calmette-guerin substrain tice live antigen | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1307,
25,
962
]
],
[
[
1307,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1307,
24,
270
],
[
270,
64,
962
]
],
[
[
1307,
63,
663
],
[
663,
... | [
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
]... | Melphalan may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab... |
DB00377 | DB00697 | 1,494 | 876 | [
"DDInter1382",
"DDInter1821"
] | Palonosetron | Tizanidine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debi... | Moderate | 1 | [
[
[
1494,
24,
876
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
876
]
],
[
[
1494,
21,
28882
],
[
28882,
60,
876
]
],
[
[
1494,
23,
112
],
[
112,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compoun... | Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Palonosetron (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Palonosetron may cause a minor interaction that can limit clinical effec... |
DB00675 | DB00745 | 888 | 307 | [
"DDInter1744",
"DDInter1236"
] | Tamoxifen | Modafinil | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Moderate | 1 | [
[
[
888,
24,
307
]
],
[
[
888,
36,
1301
],
[
1301,
40,
307
]
],
[
[
888,
63,
362
],
[
362,
40,
307
]
],
[
[
888,
24,
651
],
[
651,
4... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"L... | Tamoxifen (Compound) resembles Levacetylmethadol (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Modafinil (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin... |
DB00549 | DB08815 | 522 | 154 | [
"DDInter1955",
"DDInter1104"
] | Zafirlukast | Lurasidone | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
522,
24,
154
]
],
[
[
522,
6,
8374
],
[
8374,
45,
154
]
],
[
[
522,
21,
28714
],
[
28714,
60,
154
]
],
[
[
522,
24,
1033
],
[
1033,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Zafirlukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Zafirlukast (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Lurasidone (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpe... |
DB00450 | DB00916 | 78 | 112 | [
"DDInter603",
"DDInter1202"
] | Droperidol | Metronidazole | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
78,
23,
112
]
],
[
[
78,
21,
28640
],
[
28640,
60,
112
]
],
[
[
78,
64,
618
],
[
618,
23,
112
]
],
[
[
78,
25,
51
],
[
51,
23,
... | [
[
[
"Droperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Droperidol",
"{u} (Compound) causes {v} (Side Effect)",
"Depression"
],
[
"Depression",
"{u} (Side Effect) is c... | Droperidol (Compound) causes Depression (Side Effect) and Depression (Side Effect) is caused by Metronidazole (Compound)
Droperidol may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Droperido... |
DB00938 | DB01403 | 455 | 9 | [
"DDInter1635",
"DDInter1175"
] | Salmeterol | Methotrimeprazine | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
455,
24,
9
]
],
[
[
455,
63,
1178
],
[
1178,
40,
9
]
],
[
[
455,
63,
1164
],
[
1164,
1,
9
]
],
[
[
455,
24,
401
],
[
401,
24,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles M... |
DB12364 | DB13879 | 1,421 | 1,043 | [
"DDInter200",
"DDInter824"
] | Betrixaban | Glecaprevir | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity. Betrixaban, now developed by Portola Pharmaceuticals In... | Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. In combination with , glecaprevir is a useful therapy for patients who experienced therapeutic failure from other NS3/4A protease inhibitors. It demonstrates a high genetic ba... | Moderate | 1 | [
[
[
1421,
24,
1043
]
],
[
[
1421,
63,
971
],
[
971,
24,
1043
]
],
[
[
1421,
64,
868
],
[
868,
24,
1043
]
],
[
[
1421,
63,
1456
],
[
1456,
... | [
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glecaprevir"
]
],
[
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[... | Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Glecaprevir
Betrixaban may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may... |
DB01377 | DB04861 | 1,283 | 1,592 | [
"DDInter1119",
"DDInter1271"
] | Magnesium oxide | Nebivolol | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and... | Minor | 0 | [
[
[
1283,
23,
1592
]
],
[
[
1283,
63,
1479
],
[
1479,
23,
1592
]
],
[
[
1283,
24,
460
],
[
460,
62,
1592
]
],
[
[
1283,
62,
870
],
[
870,
... | [
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid... | Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken... |
DB01253 | DB08816 | 628 | 578 | [
"DDInter664",
"DDInter1802"
] | Ergometrine | Ticagrelor | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
628,
24,
578
]
],
[
[
628,
6,
4973
],
[
4973,
45,
578
]
],
[
[
628,
21,
28762
],
[
28762,
60,
578
]
],
[
[
628,
63,
723
],
[
723,
... | [
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Ergometrine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Ergometrine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ticagrelor (Compound)
Ergometrine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprep... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.